Chronic kidney disease (CKD) in a complex disorder. Overactivation of the mineralocorticoid receptor plays a substantial role, with binding of aldosterone causing inflammation and fibrosis that leads to kidney disfunction. Targeting the mineralocorticoid receptor by blocking aldosterone was first explored in the 1930s, and in 1960, the first mineralocorticoid receptor antagonist, spironolactone, was introduced. The first of these agents were steroidal agents, and while they are still widely prescribed, they are associated with a number of adverse effects that limit their use. This prompted the search for nonsteroidal agents that target the mineralocorticoid receptor. Three agents (apararenone, esaxerenone, and finerenone) are furthest along in development. Nephrologists involved in the care of patients with CKD should be informed about the efficacy and safety profiles of these agents in order to be prepared for their potential approval by the US FDA. This educational activity will address this knowledge gap by providing a summary of the evolution of this class of agents and an overview of the phase 3 clinical data of the nonsteroidal agents, so that clinicians are able to provide optimal care for their patients with CKD.

Earn Credit/ Learning Objectives and Disclosures
https://integrityce.com/ckdpodcast1

Integrity Continuing Education designates this podcast for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc.